These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36373673)

  • 1. Myasthenia gravis: What does a pharmacist need to know?
    Marriott M; Schwery A; VandenBerg A
    Am J Health Syst Pharm; 2023 Feb; 80(5):249-257. PubMed ID: 36373673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis.
    Pham Nguyen TP; Leonard CE; Bird SJ; Willis AW; Hamedani AG
    Muscle Nerve; 2021 Aug; 64(2):156-162. PubMed ID: 33719062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiological basis in the management of myasthenia gravis: a mini review.
    Binu A; Kumar SS; Padma UD; Madhu K
    Inflammopharmacology; 2022 Feb; 30(1):61-71. PubMed ID: 35059932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis.
    Tagliaferri AR; Narvaneni S; Azzam MH; Grist W
    Cureus; 2021 Jun; 13(6):e15581. PubMed ID: 34277203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
    Mehndiratta MM; Pandey S; Kuntzer T
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006986. PubMed ID: 25310725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and clinical classification of autoimmune myasthenia gravis.
    Berrih-Aknin S; Frenkian-Cuvelier M; Eymard B
    J Autoimmun; 2014; 48-49():143-8. PubMed ID: 24530233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
    Jones SC; Sorbello A; Boucher RM
    Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An update on myasthenia gravis].
    Martínez Torre S; Gómez Molinero I; Martínez Girón R
    Semergen; 2018; 44(5):351-354. PubMed ID: 29555378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
    Mehndiratta MM; Pandey S; Kuntzer T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on myasthenia gravis.
    Thanvi BR; Lo TC
    Postgrad Med J; 2004 Dec; 80(950):690-700. PubMed ID: 15579606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myasthenia gravis.
    Pourmand R
    Dis Mon; 1997 Feb; 43(2):65-109. PubMed ID: 9118787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study.
    Chou CC; Su IC; Chou IJ; Lin JJ; Lan SY; Wang YS; Kong SS; Chen YJ; Hsieh MY; Hung PC; Wang HS; Chou ML; Lin KL;
    BMC Neurol; 2019 Jul; 19(1):170. PubMed ID: 31319795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
    Le Panse R; Berrih-Aknin S
    Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
    Meriggioli MN; Sanders DB
    Expert Rev Clin Immunol; 2012 Jul; 8(5):427-38. PubMed ID: 22882218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Onset of myasthenia gravis in primary care. Presentation of a case].
    Álvarez-Cordovés MM; Mirpuri-Mirpuri PG; Pérez-Monje A
    Semergen; 2013 Oct; 39(7):e50-3. PubMed ID: 24095170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myasthenia gravis--current treatment standards and emerging drugs].
    Markéta K; Kamil M; Kamil K
    Ceska Slov Farm; 2011 Apr; 60(2):47-53. PubMed ID: 21650005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.